No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
INO Inovio Pharmaceuticals
- 11.0400
- +1.7600+18.97%
Close Jul 11 16:00 ET
- 11.0000
- -0.0400-0.36%
Post 19:57 ET
286.05MMarket Cap-2003P/E (TTM)
11.2700High9.4218Low862.13KVolume9.4400Open9.2800Pre Close9.21MTurnover3.38%Turnover RatioLossP/E (Static)25.91MShares14.748052wk High3.03P/B281.47MFloat Cap3.888052wk Low--Dividend TTM25.50MShs Float2352.0000Historical High--Div YieldTTM19.92%Amplitude3.8880Historical Low10.6810Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
INO-3107 Awarded The Innovation Passport Designation Under U.K. Government's Innovative Licensing And Access Pathway Granted By The ILAP Steering Group To INO-3107 For The Treatment Of Patients With Recurrent Respiratory Papillomatosis
Award recognizes the potential for INO-3107 to be the first therapeutic option in the United Kingdom for patients suffering from Recurrent Respiratory Papillomatosis (RRP)
JMP Securities Maintains Inovio Pharmaceuticals(INO.US) With Buy Rating, Maintains Target Price $18
JMP Securities analyst Roy Buchanan maintains $Inovio Pharmaceuticals(INO.US)$ with a buy rating, and maintains the target price at $18.According to TipRanks data, the analyst has a success rate of 28
Inovio Pharmaceuticals Receives 'Buy' Rating Amidst UK Regulatory Advancements and Promising RRP Treatment Outlook
Express News | Inovio Pharmaceuticals Shares Are Trading Higher After the Company Announced That INO-3107, Has Been Designated an Innovative Medicine as Part of the U.K.'s Innovative Licensing and Access Pathway
Express News | Inovio Announces Appointment of Steven Egge as Chief Commercial Officer
INOVIO Reports Inducement Grant Under Inducement Plan
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
Comments
$Inovio Pharmaceuticals(INO.US$ Company Announced That INO-3107, Has Been Designated an Innovative Medicine as Part of the U.K.'s Innovative Licensing and Access Pathway![]()
$Inovio Pharmaceuticals(INO.US$ INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights
• BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgicaltreatment for recurrent respiratory papillomatosis (RRP)
• Planning initiation of confirmatory trial for INO-3107 based on FDA feedback
• Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM ...
• BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgicaltreatment for recurrent respiratory papillomatosis (RRP)
• Planning initiation of confirmatory trial for INO-3107 based on FDA feedback
• Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM ...
$Inovio Pharmaceuticals(INO.US$ Inovio Pharmaceuticals Inc - Pricing of an Underwritten Offering of 2.5 Mln Shares of Its Common Stock at an Offering Price of $7.693 per Share
2
$Inovio Pharmaceuticals(INO.US$ Inovio Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg